JUL 22, 2015 11:32 AM PDT

Molecule Makes Ovarian Cancer Deadly

WRITTEN BY: Ilene Schneider
Ovarian cancer strikes terror in women, because symptoms may not be apparent until it is too late for appropriate treatment. There are few reliable early detection tests and few treatment options.
Canadian researchers target LKB1 molecule as problem, rather than solution, to ovarian cancer.
According to the Centers for Disease Control, all women are at risk for ovarian cancer, but older women are more likely to get it. Approximately 90 percent of women who get ovarian cancer are older than 40, and the greatest number are 60 or older. Annually, about 20,000 women in the United States get ovarian cancer. It is the eighth most common cancer and the fifth leading cause of cancer death in American women (http://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf)

Researchers at Lawson Health Research Institute in London, Ontario,
Canada have discovered a new target for ovarian cancer therapy. Contradicting other research, the Lawson study discovered that LKB1, a molecule that regulates the metabolism of many adult cells, makes the cancer cells lethal and resistant to chemotherapy. Lawson's Dr. Trevor Shepherd, who is solely dedicated to finding a cure for ovarian cancer, grows cancer cells in 3D structures, called "spheroids," to understand how they grow in patients. The sticky spheroids can attach themselves to different organs, but in the laboratory "they can sit dormant and unnoticed for months or years before growing and becoming resistant to chemotherapy," the article ."Intact LKB1 activity is required for survival of dormant cancer spheroids," Oncotarget, July 2015, explains (http://www.sciencedaily.com/releases/2015/07/150722101841.htm).

Dr. Shepherd's laboratory recently found that the spheroids activate a "stress signal." The key molecule that controls the signal is called LKB1, a primary upstream kinase of adenine monophosphate-activated protein kinase (AMPK), a necessary element in cell metabolism.

Acccording to Dr. Shepherd, "Previous studies stated that LKB1 was a tumor suppressor in ovarian cancer, meaning that tumor cells need to get rid of LKB1 to cause cancer, but our work is in direct conflict with these studies. We definitively show that ovarian cancer cells still have LKB1 and that this molecule allows ovarian cancer spheroids to change their metabolism, promote tumor cell survival and make them more resistant to chemotherapy."

By rebutting the other studies, Dr. Shepherd has discovered a target that has potential for new therapy options. As he says, "There are currently no therapies or drugs that target LKB1. Based on these findings, our lab is exploring several different strategies to understand and target LKB1 and its related molecules in ovarian cancer spheroids and developing the essential pre-clinical models to see if this can be translated to ovarian cancer patients."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 22, 2019
Cancer
NOV 22, 2019
The cancerous fear of circular extrachromosomal DNA
New research published in Nature suggests that ring-shaped extrachromosomal DNA (ecDNA) is particularly abundant in tumor cells and plays a malicious role ...
JAN 02, 2020
Genetics & Genomics
JAN 02, 2020
Mysterious Extrachromosomal DNA is Linked to Childhood Cancer
Scientists are learning more about an unusual kind of DNA that's separate from a cell's genomic DNA....
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean better diagnostics, and better diag...
FEB 18, 2020
Cancer
FEB 18, 2020
Are you at risk of endometrial cancer?
Are you concerned about endometrial cancer? New research published recently in the Journal of Medical Genetics has identified 24 genetic variants that...
Loading Comments...